Preston Roger J S, Tran Sinh, Johnson Jennifer A, Ní Áinle Fionnuala, Harmon Shona, White Barry, Smith Owen P, Jenkins P Vince, Dahlbäck Björn, O'Donnell James S
Haemostasis Research Group, Institute of Molecular Medicine, Trinity College Dublin, St James' Hospital, Dublin 8, Ireland.
J Biol Chem. 2009 Feb 27;284(9):5869-75. doi: 10.1074/jbc.M804703200. Epub 2009 Jan 6.
Platelet factor 4 (PF4) is an abundant platelet alpha-granule chemokine released following platelet activation. PF4 interacts with thrombomodulin and the gamma-carboxyglutamic acid (Gla) domain of protein C, thereby enhancing activated protein C (APC) generation by the thrombin-thrombomodulin complex. However, the protein C Gla domain not only mediates protein C activation in vivo, but also plays a critical role in modulating the diverse functional properties of APC once generated. In this study we demonstrate that PF4 significantly inhibits APC anti-coagulant activity. PF4 inhibited both protein S-dependent APC anticoagulant function in plasma and protein S-dependent factor Va (FVa) proteolysis 3- to 5-fold, demonstrating that PF4 impairs protein S cofactor enhancement of APC anticoagulant function. Using recombinant factor Va variants FVa-R506Q/R679Q and FVa-R306Q/R679Q, PF4 was shown to impair APC proteolysis of FVa at position Arg(306) by 3-fold both in the presence and absence of protein S. These data suggest that PF4 contributes to the poorly understood APC resistance phenotype associated with activated platelets. Finally, despite PF4 binding to the APC Gla domain, we show that APC in the presence of PF4 retains its ability to initiate PAR-1-mediated cytoprotective signaling. In summary, we propose that PF4 acts as a critical regulator of APC generation, but also differentially targets APC toward cytoprotective, rather than anticoagulant function at sites of vascular injury with concurrent platelet activation.
血小板因子4(PF4)是血小板活化后释放的一种丰富的血小板α颗粒趋化因子。PF4与血栓调节蛋白及蛋白C的γ-羧基谷氨酸(Gla)结构域相互作用,从而增强凝血酶-血栓调节蛋白复合物生成活化蛋白C(APC)的能力。然而,蛋白C的Gla结构域不仅在体内介导蛋白C的活化,而且在调节一旦生成的APC的多种功能特性方面也起着关键作用。在本研究中,我们证明PF4能显著抑制APC的抗凝活性。PF4使血浆中依赖蛋白S的APC抗凝功能以及依赖蛋白S的因子Va(FVa)蛋白水解作用降低3至5倍,表明PF4损害了蛋白S作为辅因子增强APC抗凝功能的作用。使用重组因子Va变体FVa-R506Q/R679Q和FVa-R306Q/R679Q,发现在有或没有蛋白S存在的情况下,PF4均能使APC对FVa在精氨酸(306)位点的蛋白水解作用降低3倍。这些数据表明,PF4与活化血小板相关的APC抵抗表型有关,而这种表型目前还了解甚少。最后,尽管PF4与APC的Gla结构域结合,但我们发现存在PF4时,APC仍保留其启动PAR-1介导的细胞保护信号的能力。总之,我们提出PF4不仅是APC生成的关键调节因子,而且在血管损伤并发血小板活化的部位,能使APC的功能有差异地转向细胞保护而非抗凝功能。